This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Epping, M. T. Articles by Bernards, R. Search for Related Content PubMed PubMed Citation Articles by Epping, M. T. Articles by Bernards, R. Related Collections Tumor Biology Tumor Biology: Inflammation and Immune Escape Cancer Immunology: Immunotherapy

A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer

Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Requests for reprints: René Bernards, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Phone: 31-205-121952; Fax: 31-205-121954; E-mail: r.bernards{at}nki.nl.

Tumor antigens are of interest as diagnostic and prognostic markers and potential therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma (PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic marker for clinical outcome. It has been shown recently that PRAME functions as a repressor of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing interest in tumor antigens as targets for therapy. (Cancer Res 2006; 66(22): 10639-42)

This article has been cited by other articles:

				V. G. Oehler, K. A. Guthrie, C. L. Cummings, K. Sabo, B. L. Wood, T. Gooley, T. Yang, M. T. Epping, Y. Shou, E. Pogosova-Agadjanyan, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells Blood, October 8, 2009; 114(15): 3299 - 3308. [Abstract] [Full Text] [PDF]

				C. Santamaria, M. C. Chillon, R. Garcia-Sanz, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, F. Ramos, T. Bernal, J. A. Queizan, M. J. Penarrubia, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia Haematologica, December 1, 2008; 93(12): 1797 - 1805. [Abstract] [Full Text] [PDF]

				M. T. Epping, L. Wang, J. A. Plumb, M. Lieb, H. Gronemeyer, R. Brown, and R. Bernards A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors PNAS, November 6, 2007; 104(45): 17777 - 17782. [Abstract] [Full Text] [PDF]

				C. Visus, D. Ito, A. Amoscato, M. Maciejewska-Franczak, A. Abdelsalem, R. Dhir, D. M. Shin, V. S. Donnenberg, T. L. Whiteside, and A. B. DeLeo Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck Cancer Res., November 1, 2007; 67(21): 10538 - 10545. [Abstract] [Full Text] [PDF]